doi:10.1210/clinem/dgaa863 Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A
Patients carrying specific genetic profiles may show superior outcomes with tirzepatide (a dual GLP-1/GIP receptor agonist) rather than semaglutide alone
Changs findings suggest that EX-4 inhibited LPS-induced iNOS expression at protein level, but not at transcriptional level, of iNOS gene via a cAMP/PKA dependent mechanism ( 4 The role of GLP-1/GLP-R in related disease 4.1 Diabetes Diabetes mellitus is characterized by increased inflammation, reflecting innate immune control disorders, and studies have shown a local intestinal intraepithelial lymphocyte (IEL)-GLP-1 receptor (GLP-1R) signaling network that controls the mucosal immune response ( 4.2 Cardiovascular disease The latest research has found that GLP-1R is widely expressed in the cardiovascular system and is involved in intracellular metabolism and signal transduction
IGF-DES Receptor Binding Specificity Competitive binding and receptor cross-linking experiments confirmed that both IGF-1 and des-(1-3)IGF-1 bind exclusively to the type 1 IGF receptor in L6 myoblasts, rat vascular smooth-muscle cells, and human lung fibroblasts with des-(1-3)IGF-1 demonstrating greater apparent potency in these assays, attributable to its low affinity for the competing 38 kDa IGFBP rather than differences in intrinsic receptor affinity
